drugset / Trial / NCT06387862

Pharmacokinetics of Inhaled Levosimendan

NCT06387862

Phase 2 Unknown 6 enrolled University Hospital Brussels
Non-randomizedSequentialOpen-labelBasic science

Summary

Determination of biological availability, time-to-peak and elimination half-life of inhaled levosimendan by administration of an inhaled- and intravenous dose of levosimendan.

Timeline

Start
2024-02-01
Primary completion
2024-11
Completion
2025-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Levosimendan Other / unclassified 12 ug/kg Inhaled